<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829957</url>
  </required_header>
  <id_info>
    <org_study_id>RAMBLE</org_study_id>
    <nct_id>NCT02829957</nct_id>
    <nct_alias>NCT02761044</nct_alias>
  </id_info>
  <brief_title>RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding</brief_title>
  <acronym>RAMBLE</acronym>
  <official_title>Randomized Trial to Test the Effect of Rivaroxaban or Apixaban on Menstrual Blood Loss in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A large proportion of women with menstruating potential with newly diagnosed VTE or atrial
      fibrillation, treated with apixaban will have less menstrual blood loss than patients
      randomized to rivaroxaban.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heavy menstrual bleeding (HMB) complicates the treatment of approximately 9-25% of patients
      treated with orally administered anti-Xa anticoagulants for venous thromboembolism (VTE,
      including either pulmonary embolism or deep vein thrombosis). In particular, recent evidence
      has suggested an increase in length and severity of menstrual bleeding for women treated with
      rivaroxaban, and this effect may be less severe apixaban treatment.(1;2) Increase in uterine
      bleeding with rivaroxaban has necessitated hysterectomy in rare cases.(3) Other complications
      of HMB include reduced drug adherence, decreased perception of wellness (quality of life) and
      anemia.(4;5) The anti-Xa agents may increase HMB more than vitamin K antagonists.(1) However,
      in the principal investigators' experience treating over 100 women of menstruating age with
      rivaroxaban for VTE with varying degree of HMB, no woman has expressed desire to switch to a
      VKA even when offered this option (unpublished data). We have successfully reduced perception
      of HMB by switching from rivaroxaban to apixaban in six patients. Comparison of published and
      supplemental data from AMPLIFY and AMPLIFY Extend to EINSTEIN and EINSTEIN extend trials also
      support a lower rate of uterine bleeding with apixaban compared with rivaroxaban, although
      exact comparisons are difficult to make.(6;9) Myers et al recently reported a 9.4% rate of
      HMB with apixaban, compared with a 25% rate of HMB with rivaroxaban.(2) Accordingly, we
      hypothesize that women with menstruating potential with newly diagnosed VTE or atrial
      fibrillation/flutter, treated with apixaban will have less menstrual blood loss than patients
      randomized to rivaroxaban.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PBAC scores</measure>
    <time_frame>3 months</time_frame>
    <description>&lt; 100 normal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of discontinuation</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients that held drug for menorrhagia</measure>
    <time_frame>1, 2, and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of major hemorrhage</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of recurrent VTE</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of crossover to another anticoagulant</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinically relevant non-major bleeding</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin concentration</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical component summary of standard from 36</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Menstruation</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>10mg BID for 7 days, then 5mg BID for three months</description>
    <arm_group_label>Apixaban</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>15mg BID for 7 days, then 20mg daily for three months</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-pregnant women, age 18-50

               -  For study purposes, evidence of negative pregnancy is accounted for by the
                  treating physician's initiation of treatment with oral anticoagulants

          -  Objectively diagnosed VTE or atrial fibrillation/flutter

          -  Patient reported active menstruation - does not apply to women who were recently
             pregnant

          -  Clinical plan and patient agreement to treat with oral anticoagulation for 3 months or
             longer

          -  Patients must have a working telephone

        Exclusion Criteria:

          -  Package insert exclusions for Eliquis (Apixban) or Xarelto (Rivaroxaban): [active
             pathological bleeding or severe hypersensitivity reaction to XARELTO or ELIQUIS (e.g.,
             anaphylactic reactions)]

          -  Plan to become pregnant in the next three months.

          -  Concomitant prescribed use of aspirin or thienopyridenes or other platelet inhibiting
             drugs

          -  Plan for surgical hysterectomy or endometrial ablation

          -  Known uterine cancer

          -  Von Willebrand's disease, or hemophilia

          -  Known coagulopathy from liver disease

          -  Conditions likely to preclude adherence to study procedures: Active intravenous drug
             use, known alcoholism, homelessness, or uncontrolled psychiatric illness.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey A Kline, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patti Hogan</last_name>
    <phone>317-962-1190</phone>
    <email>hoganpr@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kate Pettit</last_name>
    <phone>317-880-3870</phone>
    <email>klpettit@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eskenazi Health System</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>De Crem N, Peerlinck K, Vanassche T, Vanheule K, Debaveye B, Middeldorp S, Verhamme P, Peetermans M. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thromb Res. 2015 Oct;136(4):749-53. doi: 10.1016/j.thromres.2015.07.030. Epub 2015 Aug 4.</citation>
    <PMID>26272306</PMID>
  </reference>
  <reference>
    <citation>Myers B, Webster A. Heavy menstrual bleeding on Rivaroxaban - Comparison with Apixaban. Br J Haematol. 2017 Mar;176(5):833-835. doi: 10.1111/bjh.14003. Epub 2016 Mar 11.</citation>
    <PMID>26970315</PMID>
  </reference>
  <reference>
    <citation>Beam DM, Kahler ZP, Kline JA. Immediate Discharge and Home Treatment With Rivaroxaban of Low-risk Venous Thromboembolism Diagnosed in Two U.S. Emergency Departments: A One-year Preplanned Analysis. Acad Emerg Med. 2015 Jul;22(7):788-95. doi: 10.1111/acem.12711. Epub 2015 Jun 25.</citation>
    <PMID>26113241</PMID>
  </reference>
  <reference>
    <citation>Kline JA, Kahler ZP, Beam DM. Outpatient treatment of low-risk venous thromboembolism with monotherapy oral anticoagulation: patient quality of life outcomes and clinician acceptance. Patient Prefer Adherence. 2016 Apr 15;10:561-9. doi: 10.2147/PPA.S104446. eCollection 2016.</citation>
    <PMID>27143861</PMID>
  </reference>
  <reference>
    <citation>Liu Z, Doan QV, Blumenthal P, Dubois RW. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health. 2007 May-Jun;10(3):183-94. Review.</citation>
    <PMID>17532811</PMID>
  </reference>
  <reference>
    <citation>Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29;369(9):799-808. doi: 10.1056/NEJMoa1302507. Epub 2013 Jul 1.</citation>
    <PMID>23808982</PMID>
  </reference>
  <reference>
    <citation>EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23;363(26):2499-510. doi: 10.1056/NEJMoa1007903. Epub 2010 Dec 3.</citation>
    <PMID>21128814</PMID>
  </reference>
  <reference>
    <citation>EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26.</citation>
    <PMID>22449293</PMID>
  </reference>
  <reference>
    <citation>Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):699-708. doi: 10.1056/NEJMoa1207541. Epub 2012 Dec 8.</citation>
    <PMID>23216615</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 6, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>December 4, 2019</last_update_submitted>
  <last_update_submitted_qc>December 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Jeffrey Kline</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

